# Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19

> **NCT05387239** · PHASE2 · SUSPENDED · sponsor: **Vitti Labs, LLC** · enrollment: 20 (estimated)

## Conditions studied

- Pulmonary Fibrosis
- COVID-19 Respiratory Infection

## Interventions

- **DRUG:** VL-PX10 and VL-P22 plus standard care
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05387239
- **Lead sponsor:** Vitti Labs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-11-30
- **Primary completion:** 2024-11
- **Final completion:** 2024-12
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Sponsor request
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387239, "Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05387239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*